Adagio Medical Holdings, Inc. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Requirement
Key Points for Investors:
- Adagio Medical Holdings, Inc. (NASDAQ: ADGM) has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on June 12, 2026, regarding non-compliance with the minimum bid price requirement.
- The company’s common stock failed to maintain a minimum closing bid price of \$1.00 per share for 30 consecutive business days, as required under Nasdaq Listing Rule 5550(a)(2).
- Adagio Medical’s common stock will continue to be listed and traded on the Nasdaq Capital Market, but the company has been given a 180-day grace period—until December 9, 2026—to regain compliance with the minimum bid price rule.
- If during this period, the stock price closes at or above \$1.00 per share for at least ten consecutive trading days, the company will be deemed compliant again and no further action will be necessary.
- If compliance is not regained by the deadline, a second 180-day compliance period may be available, provided the company notifies Nasdaq in writing of its intent to regain compliance, potentially by effecting a reverse stock split if necessary, and meets all other continued listing requirements except for the bid price rule.
- If the company fails to regain compliance during the second grace period or does not qualify for it, Nasdaq will proceed to delist the company’s common stock.
Important Information for Shareholders:
- This notification is material and may be price-sensitive. The risk of potential delisting can significantly impact investor sentiment and the market valuation of Adagio Medical Holdings, Inc.
- Delisting from Nasdaq could lead to reduced liquidity, lower trading volumes, and a potential decrease in share price, making it more difficult for shareholders to buy or sell shares.
- Management is “considering all available options” to regain compliance, including the possibility of a reverse stock split, which typically reduces the number of shares outstanding and increases the share price, but does not change the company’s total market capitalization.
- There is no assurance that the company will be able to regain compliance within the specified periods, or that it will continue to meet other Nasdaq listing requirements.
- Shareholders should closely monitor further communications from the company as future actions, such as a reverse stock split or delisting, could materially affect the value of their investment.
Additional Company and Stock Information:
- Company Name: Adagio Medical Holdings, Inc.
- Trading Symbol: ADGM
- Exchange: The Nasdaq Stock Market LLC
- Security: Common Stock, par value \$0.0001 per share
- Address: 26051 Merit Circle, Suite 102, Laguna Hills, CA 92653
- Phone: (949) 348-1188
- Chief Financial Officer and Chief Business Officer: Deborah Kaster
- Emerging Growth Company: Yes
What’s Next?
- Investors should expect ongoing updates from the company regarding its efforts to regain compliance.
- Any corporate actions, such as a reverse stock split or further developments regarding the Nasdaq listing, will be particularly important and could impact the share price.
- Failure to regain compliance could result in the stock being delisted from Nasdaq, which is typically viewed negatively by the market.
Disclaimer: This report is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information herein is based on filings and disclosures made by Adagio Medical Holdings, Inc. as of June 12, 2026, and may be subject to change.
